Article
Oncology
Hideyuki Furumoto, Ryuhei Okada, Takuya Kato, Hiroaki Wakiyama, Fuyuki Inagaki, Hiroshi Fukushima, Shuhei Okuyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a cancer therapy that selectively destroys target cells by injecting monoclonal antibodies conjugated with a photon absorber and activating it with nonthermal doses of NIR light. Higher light doses can enhance the therapeutic effect but may cause local side effects, while lower doses can be effective and avoid side effects. This study determined the optimal light dose for NIR-PIT in an immunocompetent mouse model. It was found that a relatively low light dose is sufficient to achieve the maximum therapeutic effect without causing side effects.
Article
Gastroenterology & Hepatology
Tadanobu Nagaya, Peter L. Choyke, Hisataka Kobayashi
Summary: This article reviews a newly developed cancer therapy called near-infrared photoimmunotherapy (NIR-PIT), which is a highly selective tumor treatment activated by near-infrared light. NIR-PIT differs from conventional therapies in targeting cancer cells and causing immunogenic cell death. Preclinical research combining NIR-PIT with other cancer immunotherapies shows promise for local and distant tumor responses.
Review
Medicine, General & Internal
Yasuhiro Maruoka, Hiroaki Wakiyama, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a highly-selective cancer treatment using a photoabsorbing dye, currently undergoing global phase III clinical trials and conditionally approved in Japan. In addition to rapid, selective cancer cell death, it also stimulates anti-tumour immunity and may have improved results in combination with immune-checkpoint inhibitors.
Article
Multidisciplinary Sciences
Hirotoshi Yasui, Yuko Nishinaga, Shunichi Taki, Kazuomi Takahashi, Yoshitaka Isobe, Kazuhide Sato
Summary: Photoimmunotherapy efficacy can be more accurately evaluated in an orthotopic mouse model than in a subcutaneous one. A pleural dissemination model is useful for assessing treatment methods for thoracic diseases, and near-infrared photoimmunotherapy (NIR-PIT) is a promising cancer treatment strategy combining tumor-targeting antibodies with photoabsorber-induced toxicity.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2021)
Article
Medicine, General & Internal
Kohei Matsuoka, Mizuki Yamada, Noriaki Fukatsu, Kyoichi Goto, Misae Shimizu, Ayako Kato, Yoshimi Kato, Hiroshi Yukawa, Yoshinobu Baba, Mitsuo Sato, Kazuhide Sato
Summary: Monitoring the effectiveness of NIR-PIT can be done by measuring SUPR. In this study, fluorescent signals and ultrasound imaging were used to evaluate SUPR, and indicators related to therapeutic effect were discovered.
Article
Oncology
Susumu Yamashita, Miho Kojima, Nobuhiko Onda, Makoto Shibutani
Summary: This study compared the properties and differences of near-infrared photoimmunotherapy (NIR-PIT) and photodynamic therapy (PDT) in terms of cellular binding/uptake specificity and cytotoxicity. NIR-PIT showed molecule-selective responses and cytotoxicity, while PDT showed non-selective cell type responses. Both NIR-PIT and PDT induced damage-associated molecular patterns (DAMPs), although PDT had different sensitivity between cell lines. Therefore, molecule-specific NIR-PIT may have advantages compared with PDT in terms of tumor visualization efficiency and induction of DAMPs.
Review
Oncology
Irene Paraboschi, Stephen Turnock, Gabriela Kramer-Marek, Layla Musleh, Marta Barisa, John Anderson, Stefano Giuliani
Summary: NIR-PIT is a novel cancer-targeted treatment that involves a chemical conjugation between a photosensitiser and a cancer-targeting moiety, leading to accumulation at the tumor cell surface and targeted cell death upon NIR-light irradiation. While the mechanisms of action are not fully understood, researchers are working to address key unanswered research questions.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Medicine, Research & Experimental
Fuyuki F. Inagaki, Hiroaki Wakiyama, Aki Furusawa, Ryuhei Okada, Takuya Kato, Daiki Fujimura, Shuhei Okuyama, Hiroshi Fukushima, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi
Summary: Bones are a common site for metastasis from solid tumors, and current treatments are not curative. Near-infrared photoimmunotherapy (NIR-PIT), which uses antibodies labeled with IRDye700DX (IR700) activated by NIR light, has shown success in treating head and neck cancer but has not been tested on bone metastases. This study investigated the efficacy of EGFR-targeted NIR-PIT on bone metastatic lesions using a mouse model and found that it had a therapeutic effect and could repair metastasis-induced bone destruction.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Hiroaki Sato, Kazuhiro Noma, Toshiaki Ohara, Kento Kawasaki, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Toru Narusaka, Satoshi Komoto, Hajime Kashima, Yuki Katsura, Takuya Kato, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara
Summary: This study investigated the efficacy of dual-targeted near-infrared photoimmunotherapy (NIR-PIT) as a therapeutic strategy for cancer treatment. The results showed that dual-targeted NIR-PIT had specific therapeutic effects on both cancer cells and cancer-associated fibroblasts (CAFs), suppressing tumor growth in vivo. Therefore, dual-targeted NIR-PIT may be a promising therapeutic strategy for cancer treatment.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Hiroshi Fukushima, Baris Turkbey, Peter A. Pinto, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel molecularly-targeted therapy that selectively kills cancer cells by injecting an antibody-photoabsorber conjugate (APC) that binds to cancer cells, followed by the application of NIR light. NIR-PIT can selectively kill cancer cells without harming normal tissues and activates anti-cancer immunity.
Review
Biochemistry & Molecular Biology
Kohei Matsuoka, Mizuki Yamada, Mitsuo Sato, Kazuhide Sato
Summary: The conventional treatment for thoracic tumors includes surgery, drugs, radiation, and immunotherapy. Recently, near-infrared photoimmunotherapy (NIR-PIT) has emerged as a promising therapeutic approach for thoracic tumors. By targeting different antigens, NIR-PIT can be applied to any desired target.
Review
Nanoscience & Nanotechnology
Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that selectively kills cancer cells using targeting monoclonal antibodies and photoactivatable phthalocyanine-derivative dyes, leading to minimal damage to patients and rapid recovery. Additionally, it activates host antitumor immunity and enhances nanodrug delivery to tumor beds.
Article
Immunology
Federica Calo, Lorenzo Onorato, Mariantonietta Pisaturo, Antonio Pinto, Loredana Alessio, Caterina Monari, Carmine Minichini, Manuela Arcamone, Alessandra Di Fraia, Luigi Atripaldi, Claudia Tiberio, Nicola Coppola
Summary: There is limited data regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. This report presents the virological and clinical characteristics of a patient with follicle center lymphoma who was infected by the SARS-CoV-2 Omicron variant despite receiving three doses of the BNT162b2 vaccine. The patient initially experienced remission due to early therapy with sotrovimab, but suffered a fatal relapse caused by the same viral strain.
Article
Oncology
Fuyuki F. Inagaki, Daiki Fujimura, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Takuya Kato, Peter L. Choyke, Hisataka Kobayashi
Summary: NIR-PIT is a novel cancer treatment approved in Japan for inoperable head and neck cancer patients, utilizing specific wavelength NIR light to induce cell death. By using an ICG camera, real-time detection of IR700 fluorescence can visualize target tumors.
Article
Medicine, Research & Experimental
Fuyuki F. Inagaki, Daiki Fujimura, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Takuya Kato, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that utilizes specific wavelength near-infrared light to target tumor cells for treatment. Research has shown that conjugation of a second near-infrared dye prior to NIR-PIT can provide real-time feedback on tumor location.
MOLECULAR PHARMACEUTICS
(2021)
Article
Oncology
Jiefu Jin, Ishwarya Sivakumar, Yelena Mironchik, Balaji Krishnamachary, Flonne Wildes, James D. Barnett, Chien-Fu Hung, Sridhar Nimmagadda, Hisataka Kobayashi, Zaver M. Bhujwalla, Marie-France Penet
Summary: Ovarian cancer is a major cause of death in women in the United States, and current treatments for advanced stage disease are not satisfactory. This study found that photoimmunotherapy can eliminate cell populations expressing PD-L1 in ovarian cancer, suggesting it as a potential therapeutic option.
Article
Oncology
Hiroaki Wakiyama, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: The study evaluates the anti-tumor efficacy of VISTA-targeted NIR-PIT in murine tumor models. Results show that VISTA-targeted NIR-PIT enhances anti-tumor immune responses by depleting immune suppressor cells, inhibits tumor progression, and prolongs survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Nanoscience & Nanotechnology
Minchuan Luo, Hiroshi Yukawa, Kazuhide Sato, Makoto Tozawa, Masato Tokunaga, Tatsuya Kameyama, Tsukasa Torimoto, Yoshinobu Baba
Summary: This study presents a multifunctional nanoprobe for bimodal imaging and photothermal-enhanced targeted therapy. The nanoprobe exhibits intense fluorescence and magnetic resonance imaging capabilities for sensitive and high-resolution imaging of tumors in living mice. Additionally, it can generate localized heat and reactive oxygen species, achieving excellent therapeutic efficacy in vivo.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Respiratory System
Takayasu Ito, Shotaro Okachi, Kazuhide Sato, Hirotoshi Yasui, Noriaki Fukatsu, Masahiko Ando, Toyofumi Fengshi Chen-Yoshikawa, Hideo Saka
Summary: This study evaluated the use of an e-mask during bronchoscopy and found that it significantly reduced the generation of airborne particles, while not increasing the risk of respiratory complications.
Review
Biochemistry & Molecular Biology
Kohei Matsuoka, Mizuki Yamada, Mitsuo Sato, Kazuhide Sato
Summary: The conventional treatment for thoracic tumors includes surgery, drugs, radiation, and immunotherapy. Recently, near-infrared photoimmunotherapy (NIR-PIT) has emerged as a promising therapeutic approach for thoracic tumors. By targeting different antigens, NIR-PIT can be applied to any desired target.
Article
Oncology
Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that utilizes an antibody-IRDye700DX (IR700) conjugate and NIR light to induce cell membrane damage and cell death. PDPN-targeted NIR-PIT showed efficacy in destroying cancer cells and cancer-associated fibroblasts (CAFs), suppressing tumor progression, and enhancing host antitumor immunity.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Oncology
Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: This study demonstrates the use of NIR-PIT to deplete CD8(+) T cells and temporarily change the balance of T-cell subsets in the tumor microenvironment, leading to rapid tumor progression after PD-1 blockade therapy. The results suggest that imbalances between effector T cells and regulatory T cells in the tumor microenvironment may contribute to hyperprogressive disease following PD-1 blockade therapy.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Hideyuki Furumoto, Ryuhei Okada, Takuya Kato, Hiroaki Wakiyama, Fuyuki Inagaki, Hiroshi Fukushima, Shuhei Okuyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a cancer therapy that selectively destroys target cells by injecting monoclonal antibodies conjugated with a photon absorber and activating it with nonthermal doses of NIR light. Higher light doses can enhance the therapeutic effect but may cause local side effects, while lower doses can be effective and avoid side effects. This study determined the optimal light dose for NIR-PIT in an immunocompetent mouse model. It was found that a relatively low light dose is sufficient to achieve the maximum therapeutic effect without causing side effects.
Article
Pharmacology & Pharmacy
Fuyuki F. Inagaki, Takuya Kato, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: This study investigated the feasibility of GD2-targeted NIR-PIT in cancer treatment and found that GD2-targeted NIR-PIT effectively inhibits tumor growth and activates host immunity, demonstrating that membrane glycolipids can be a new target for NIR-PIT.
Article
Oncology
Takuya Kato, Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi
Summary: The immune system plays a crucial role in regulating cancer development, progression, and metastasis. Near-infrared photoimmunotherapy (NIR-PIT) is a promising new treatment that selectively kills targeted cells without damaging adjacent normal cells. This study evaluated the effectiveness of MDSC-directed NIR-PIT in the tumor microenvironment, resulting in significant tumor growth suppression and prolonged survival in mouse models.
Review
Biochemistry & Molecular Biology
Hisataka Kobayashi, Peter L. Choyke, Mikako Ogawa
Summary: Near infrared photoimmunotherapy (NIR-PIT) is a new cancer therapy that utilizes the photo-induced ligand release reaction of a silicon-phthalocyanine derivative, IRDye700DX (IR700), to cause rapid cell death. When exposed to NIR light, cells conjugated with an anti-body-IR700 compound undergo swelling, blebbing, and bursting within minutes. The ligand release reaction also leads to immediate loss of IR700 fluorescence, enabling real time monitoring of NIR-PIT therapy.
CURRENT OPINION IN CHEMICAL BIOLOGY
(2023)
Article
Oncology
Seiichiro Takao, Hiroshi Fukushima, A. Paden King, Takuya Kato, Aki Furusawa, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Freddy E. Escorcia, Hisataka Kobayashi
Summary: This study investigates the application of NIR-PIT using cetuximab-IR700 to HCCs and demonstrates its potential for killing cancer cells and delaying growth.
Article
Biochemical Research Methods
Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga
Summary: Microbial pathogens can develop resistance to drugs, so finding new therapeutic agents is crucial. This article introduces a photoimmuno-antimicrobial strategy (PIAS) that uses specific antibodies and dyes to target a wide range of microbes, including the SARS-CoV-2 virus and MRSA bacteria.
Review
Oncology
Nanami L. Miyazaki, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: RM-1929 NIR-PIT is an emerging treatment that has been shown to be well-tolerated and clinically meaningful for patients with unresectable and/or recurrent head and neck squamous cell carcinoma.
Article
Chemistry, Multidisciplinary
Hajime Shigemitsu, Kei Ohkubo, Kazuhide Sato, Asuka Bunno, Tadashi Mori, Yasuko Osakada, Mamoru Fujitsuka, Toshiyuki Kida
Summary: In this study, a strategy to form type I supramolecular photosensitizers (SPSs) utilizing charge-separated state induced by self-assembly was proposed. The switching mechanism from type II to I via self-assembly was clarified using photophysical and electrochemical analyses. The type I SPS demonstrated significant photodynamic therapy effects on cancer cells, providing a promising approach for the development of type I photosensitizers based on supramolecular assemblies.
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)
